
|Videos|August 22, 2022
Study shows potential of ctDNA as biomarker for immunotherapy response in GU cancers
Author(s)Urology Times staff
Albert Jang, MD, discusses the promise of using ctDNA to determine whether patients with advanced genitourinary cancers are responding to immune checkpoint inhibitors.
Advertisement
Albert Jang, MD, a 3rd-year internal resident physician at Tulane University, discusses the study, “Prospective Evaluation Of Circulating Tumor Dna (ctDNA) in Detecting Early Progression on Immune Checkpoint Inhibitors in Patients With Advanced Genitourinary Cancers,” which he shared at the 2022 AUA Annual Meeting.
Newsletter
Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA grants clearance to Hugo robotic-assisted surgery system for urologic procedures
2
Apalutamide is linked to fewer CNS-related conditions in patients with nmCRPC
3
Prostate MRI is linked with higher sensitivity, NPV vs micro-ultrasound in pilot study
4
Michael Cookson, MD, discusses new strategies for treatment intensification in prostate cancer
5


















